A randomized trial comparing safety, immunogenicity and efficacy of self-amplifying mRNA and adenovirus-vector COVID-19 vaccines
Abstract This phase 3 trial compared safety, tolerability, immunogenicity and efficacy of the self-amplifying mRNA COVID-19 vaccine, ARCT-154, with ChAdOx1-S adenovirus-vector vaccine. In four centers in Vietnam adult participants aged 18‒85 years were randomly assigned to receive two doses, 28 days...
        Saved in:
      
    
          | Main Authors: | , , , , , , , , , , , , , , , , , | 
|---|---|
| Format: | Article | 
| Language: | English | 
| Published: | Nature Portfolio
    
        2024-11-01 | 
| Series: | npj Vaccines | 
| Online Access: | https://doi.org/10.1038/s41541-024-01017-5 | 
| Tags: | Add Tag 
      No Tags, Be the first to tag this record!
   | 
 
       